Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19

This paper raises concerns about use of hydroxychloroquine with azithromycin in the treatment of COVID-19, as both prolong the QT interval. It discusses risks and suggested monitoring, and calls for all use outside a clinical trial to have cardiology input.

SPS commentary:

Clinicians in some studies have started using these medicines in clinical practice following the results of preliminary research in France, suggesting hydroxychloroquine alone or in combination with azithromycin shortened time to resolution of COVID-19 viral shedding. This article notes that the use of hydroxychloroquine or chloroquine therapy should only occur in the context of a clinical trial or registry, until sufficient evidence is available to support use in clinical practice.

The MHRA recently issued a reminder that chloroquine and hydroxychloroquine should only be used for the treatment of COVID-19 within a clinical trial, until there is clear, definitive evidence that they are safe and effective.

Cardiology Magazine

Resource links:

MHRA advice